title: Chronic treatment with a broad-spectrum metalloproteinase inhibitor, doxycycline, prevents the development of spontaneous aortic lesions in a mouse model of vascular Ehlers-Danlos syndrome.
abstract: There is no proven therapy or prevention for vascular Ehlers-Danlos syndrome (vEDS), a genetic disorder associated with the mutation of procollagen type III and characterized by increased fragility of vascular and hollow organ walls. Heterozygous COL3A1-deficient (HT) mice recapitulate a mild presentation of one of the variants of vEDS: haploinsufficiency for collagen III. Adult HT mice are characterized by increased metalloproteinase (MMP) activity, reduced collagen content in the arterial walls, and spontaneous development of various severity lesions in aorta. We hypothesized that chronic treatment with a MMP inhibitor would increase collagen content and prevent the development of spontaneous aortic lesions. HT mice were treated since weaning with the broad-spectrum MMP inhibitor doxycycline added to food. At the age of 9 months MMP-9 expression was twice as high in the tunica media of aorta in untreated HT mice, whereas total collagen content was 30% lower (p < 0.01) and the cumulative score of aortic lesions was eight times higher than in wild-type (WT) mice (p < 0.01). After 9 months of doxycycline treatment, MMP-9 activity, collagen content, and lesions in the aortas of HT mice were at the level of those of WT mice (p > 0.05). In the mouse model of collagen III haploinsufficiency treatment with broad-spectrum MMP inhibitor that was started early in life normalized increased MMP activity, reduced aortic collagen content in adults, and prevented the development of spontaneous aortic lesions. Our findings provide experimental justification for the clinical evaluation of the benefit of doxycycline at least in the haploinsufficient variety of vEDS.
authors: Laboratory of Cardiovascular Science, National Institute on Aging, Baltimore, MD 21224, USA.
authors: Hyun-Jin
authors: HJ
authors: Tae
authors: Shannon
authors: S
authors: Marshall
authors: Jing
authors: J
authors: Zhang
authors: Mingyi
authors: M
authors: Wang
authors: Wilfried
authors: W
authors: Briest
authors: Mark I
authors: MI
authors: Talan
mesh_terms: D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D004195:Disease Models, Animal; D004318:Doxycycline / Q000008:administration & dosage*; D004535:Ehlers-Danlos Syndrome / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology*; D061965:Matrix Metalloproteinase Inhibitors / Q000008:administration & dosage*; D051379:Mice; D018345:Mice, Knockout; D016896:Treatment Outcome
chemical_list: D061965:Matrix Metalloproteinase Inhibitors; D004318:Doxycycline